BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rebuzzi SE, Banna GL, Murianni V, Damassi A, Giunta EF, Fraggetta F, De Giorgi U, Cathomas R, Rescigno P, Brunelli M, Fornarini G. Prognostic and Predictive Factors in Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Review of the Current Evidence. Cancers (Basel) 2021;13:5517. [PMID: 34771680 DOI: 10.3390/cancers13215517] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Voutsadakis IA. Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies. Current Oncology 2022;29:1390-407. [DOI: 10.3390/curroncol29030117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Califano G, Ouzaid I, Laine-caroff P, Peyrottes A, Collà Ruvolo C, Pradère B, Elalouf V, Misrai V, Hermieu J, Shariat SF, Xylinas E. Current Advances in Immune Checkpoint Inhibition and Clinical Genomics in Upper Tract Urothelial Carcinoma: State of the Art. Current Oncology 2022;29:687-97. [DOI: 10.3390/curroncol29020060] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 López-fernández E, Angulo JC, López JI, Manini C. Urological Cancer Panorama in the Second Year of the COVID-19 Pandemic. Cancers 2022;14:493. [DOI: 10.3390/cancers14030493] [Reference Citation Analysis]